Evidence map›Paper›PMID 36607243›Full record

ArticleRadiology. Imaging cancer2023

Volumetric Enhancing Tumor Burden at CT to Predict Survival Outcomes in Patients with Neuroendocrine Liver Metastases after Intra-arterial Treatment.

Jessica Assouline, Roberto Cannella, Giorgia Porrello, Louis de Mestier, Marco Dioguardi Burgio, Lucas Raynaud, Olivia Hentic, Jérôme Cros, Lambros Tselikas, Philippe Ruszniewski and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiology. Imaging cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 3 countries.

Jessica AssoulineFrom the Departments of Radiology (J.A., R.C., G.P., M.D., L.R., M.P.V., V.V., M.R.), Pancreatology and Digestive Oncology (L.d.M., O.H., P.R.), and Pathology (J.C.), Université de Paris, ENETS Centre of Excellence, Beaujon Hospital (APHP), Clichy, France; Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University Hospital Paolo Giaccone, Palermo, Italy (R.C., G.P.); Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy (R.C.); Université de Paris, Centre of Research on Inflammation, INSERM U1149, Paris, France (L.d.M., M.D., J.C., V.V., M.R.); Gustave Roussy, Département d'Anesthésie, Chirurgie et Interventionnel (DACI), Villejuif, France (L.T.); and Lausanne University Hospital and University of Lausanne, Department of Radiology and Interventional Radiology, Lausanne, Switzerland (R.D.).
Roberto CannellaFrom the Departments of Radiology (J.A., R.C., G.P., M.D., L.R., M.P.V., V.V., M.R.), Pancreatology and Digestive Oncology (L.d.M., O.H., P.R.), and Pathology (J.C.), Université de Paris, ENETS Centre of Excellence, Beaujon Hospital (APHP), Clichy, France; Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University Hospital Paolo Giaccone, Palermo, Italy (R.C., G.P.); Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy (R.C.); Université de Paris, Centre of Research on Inflammation, INSERM U1149, Paris, France (L.d.M., M.D., J.C., V.V., M.R.); Gustave Roussy, Département d'Anesthésie, Chirurgie et Interventionnel (DACI), Villejuif, France (L.T.); and Lausanne University Hospital and University of Lausanne, Department of Radiology and Interventional Radiology, Lausanne, Switzerland (R.D.).ORCID 0000-0002-3808-0785
Giorgia PorrelloFrom the Departments of Radiology (J.A., R.C., G.P., M.D., L.R., M.P.V., V.V., M.R.), Pancreatology and Digestive Oncology (L.d.M., O.H., P.R.), and Pathology (J.C.), Université de Paris, ENETS Centre of Excellence, Beaujon Hospital (APHP), Clichy, France; Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University Hospital Paolo Giaccone, Palermo, Italy (R.C., G.P.); Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy (R.C.); Université de Paris, Centre of Research on Inflammation, INSERM U1149, Paris, France (L.d.M., M.D., J.C., V.V., M.R.); Gustave Roussy, Département d'Anesthésie, Chirurgie et Interventionnel (DACI), Villejuif, France (L.T.); and Lausanne University Hospital and University of Lausanne, Department of Radiology and Interventional Radiology, Lausanne, Switzerland (R.D.).ORCID 0000-0003-1617-5609
Louis de MestierFrom the Departments of Radiology (J.A., R.C., G.P., M.D., L.R., M.P.V., V.V., M.R.), Pancreatology and Digestive Oncology (L.d.M., O.H., P.R.), and Pathology (J.C.), Université de Paris, ENETS Centre of Excellence, Beaujon Hospital (APHP), Clichy, France; Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University Hospital Paolo Giaccone, Palermo, Italy (R.C., G.P.); Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy (R.C.); Université de Paris, Centre of Research on Inflammation, INSERM U1149, Paris, France (L.d.M., M.D., J.C., V.V., M.R.); Gustave Roussy, Département d'Anesthésie, Chirurgie et Interventionnel (DACI), Villejuif, France (L.T.); and Lausanne University Hospital and University of Lausanne, Department of Radiology and Interventional Radiology, Lausanne, Switzerland (R.D.).
Marco Dioguardi BurgioFrom the Departments of Radiology (J.A., R.C., G.P., M.D., L.R., M.P.V., V.V., M.R.), Pancreatology and Digestive Oncology (L.d.M., O.H., P.R.), and Pathology (J.C.), Université de Paris, ENETS Centre of Excellence, Beaujon Hospital (APHP), Clichy, France; Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University Hospital Paolo Giaccone, Palermo, Italy (R.C., G.P.); Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy (R.C.); Université de Paris, Centre of Research on Inflammation, INSERM U1149, Paris, France (L.d.M., M.D., J.C., V.V., M.R.); Gustave Roussy, Département d'Anesthésie, Chirurgie et Interventionnel (DACI), Villejuif, France (L.T.); and Lausanne University Hospital and University of Lausanne, Department of Radiology and Interventional Radiology, Lausanne, Switzerland (R.D.).ORCID 0000-0002-3243-6699
Lucas RaynaudFrom the Departments of Radiology (J.A., R.C., G.P., M.D., L.R., M.P.V., V.V., M.R.), Pancreatology and Digestive Oncology (L.d.M., O.H., P.R.), and Pathology (J.C.), Université de Paris, ENETS Centre of Excellence, Beaujon Hospital (APHP), Clichy, France; Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University Hospital Paolo Giaccone, Palermo, Italy (R.C., G.P.); Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy (R.C.); Université de Paris, Centre of Research on Inflammation, INSERM U1149, Paris, France (L.d.M., M.D., J.C., V.V., M.R.); Gustave Roussy, Département d'Anesthésie, Chirurgie et Interventionnel (DACI), Villejuif, France (L.T.); and Lausanne University Hospital and University of Lausanne, Department of Radiology and Interventional Radiology, Lausanne, Switzerland (R.D.).
Olivia HenticFrom the Departments of Radiology (J.A., R.C., G.P., M.D., L.R., M.P.V., V.V., M.R.), Pancreatology and Digestive Oncology (L.d.M., O.H., P.R.), and Pathology (J.C.), Université de Paris, ENETS Centre of Excellence, Beaujon Hospital (APHP), Clichy, France; Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University Hospital Paolo Giaccone, Palermo, Italy (R.C., G.P.); Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy (R.C.); Université de Paris, Centre of Research on Inflammation, INSERM U1149, Paris, France (L.d.M., M.D., J.C., V.V., M.R.); Gustave Roussy, Département d'Anesthésie, Chirurgie et Interventionnel (DACI), Villejuif, France (L.T.); and Lausanne University Hospital and University of Lausanne, Department of Radiology and Interventional Radiology, Lausanne, Switzerland (R.D.).
Jérôme CrosFrom the Departments of Radiology (J.A., R.C., G.P., M.D., L.R., M.P.V., V.V., M.R.), Pancreatology and Digestive Oncology (L.d.M., O.H., P.R.), and Pathology (J.C.), Université de Paris, ENETS Centre of Excellence, Beaujon Hospital (APHP), Clichy, France; Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University Hospital Paolo Giaccone, Palermo, Italy (R.C., G.P.); Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy (R.C.); Université de Paris, Centre of Research on Inflammation, INSERM U1149, Paris, France (L.d.M., M.D., J.C., V.V., M.R.); Gustave Roussy, Département d'Anesthésie, Chirurgie et Interventionnel (DACI), Villejuif, France (L.T.); and Lausanne University Hospital and University of Lausanne, Department of Radiology and Interventional Radiology, Lausanne, Switzerland (R.D.).
Lambros TselikasFrom the Departments of Radiology (J.A., R.C., G.P., M.D., L.R., M.P.V., V.V., M.R.), Pancreatology and Digestive Oncology (L.d.M., O.H., P.R.), and Pathology (J.C.), Université de Paris, ENETS Centre of Excellence, Beaujon Hospital (APHP), Clichy, France; Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University Hospital Paolo Giaccone, Palermo, Italy (R.C., G.P.); Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy (R.C.); Université de Paris, Centre of Research on Inflammation, INSERM U1149, Paris, France (L.d.M., M.D., J.C., V.V., M.R.); Gustave Roussy, Département d'Anesthésie, Chirurgie et Interventionnel (DACI), Villejuif, France (L.T.); and Lausanne University Hospital and University of Lausanne, Department of Radiology and Interventional Radiology, Lausanne, Switzerland (R.D.).ORCID 0000-0001-7732-6293
Philippe RuszniewskiFrom the Departments of Radiology (J.A., R.C., G.P., M.D., L.R., M.P.V., V.V., M.R.), Pancreatology and Digestive Oncology (L.d.M., O.H., P.R.), and Pathology (J.C.), Université de Paris, ENETS Centre of Excellence, Beaujon Hospital (APHP), Clichy, France; Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University Hospital Paolo Giaccone, Palermo, Italy (R.C., G.P.); Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy (R.C.); Université de Paris, Centre of Research on Inflammation, INSERM U1149, Paris, France (L.d.M., M.D., J.C., V.V., M.R.); Gustave Roussy, Département d'Anesthésie, Chirurgie et Interventionnel (DACI), Villejuif, France (L.T.); and Lausanne University Hospital and University of Lausanne, Department of Radiology and Interventional Radiology, Lausanne, Switzerland (R.D.).
Marie-Pierre VulliermeFrom the Departments of Radiology (J.A., R.C., G.P., M.D., L.R., M.P.V., V.V., M.R.), Pancreatology and Digestive Oncology (L.d.M., O.H., P.R.), and Pathology (J.C.), Université de Paris, ENETS Centre of Excellence, Beaujon Hospital (APHP), Clichy, France; Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University Hospital Paolo Giaccone, Palermo, Italy (R.C., G.P.); Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy (R.C.); Université de Paris, Centre of Research on Inflammation, INSERM U1149, Paris, France (L.d.M., M.D., J.C., V.V., M.R.); Gustave Roussy, Département d'Anesthésie, Chirurgie et Interventionnel (DACI), Villejuif, France (L.T.); and Lausanne University Hospital and University of Lausanne, Department of Radiology and Interventional Radiology, Lausanne, Switzerland (R.D.).
Valérie VilgrainFrom the Departments of Radiology (J.A., R.C., G.P., M.D., L.R., M.P.V., V.V., M.R.), Pancreatology and Digestive Oncology (L.d.M., O.H., P.R.), and Pathology (J.C.), Université de Paris, ENETS Centre of Excellence, Beaujon Hospital (APHP), Clichy, France; Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University Hospital Paolo Giaccone, Palermo, Italy (R.C., G.P.); Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy (R.C.); Université de Paris, Centre of Research on Inflammation, INSERM U1149, Paris, France (L.d.M., M.D., J.C., V.V., M.R.); Gustave Roussy, Département d'Anesthésie, Chirurgie et Interventionnel (DACI), Villejuif, France (L.T.); and Lausanne University Hospital and University of Lausanne, Department of Radiology and Interventional Radiology, Lausanne, Switzerland (R.D.).ORCID 0000-0002-3568-7725
Rafael DuranFrom the Departments of Radiology (J.A., R.C., G.P., M.D., L.R., M.P.V., V.V., M.R.), Pancreatology and Digestive Oncology (L.d.M., O.H., P.R.), and Pathology (J.C.), Université de Paris, ENETS Centre of Excellence, Beaujon Hospital (APHP), Clichy, France; Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University Hospital Paolo Giaccone, Palermo, Italy (R.C., G.P.); Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy (R.C.); Université de Paris, Centre of Research on Inflammation, INSERM U1149, Paris, France (L.d.M., M.D., J.C., V.V., M.R.); Gustave Roussy, Département d'Anesthésie, Chirurgie et Interventionnel (DACI), Villejuif, France (L.T.); and Lausanne University Hospital and University of Lausanne, Department of Radiology and Interventional Radiology, Lausanne, Switzerland (R.D.).ORCID 0000-0003-2610-9517
Maxime RonotFrom the Departments of Radiology (J.A., R.C., G.P., M.D., L.R., M.P.V., V.V., M.R.), Pancreatology and Digestive Oncology (L.d.M., O.H., P.R.), and Pathology (J.C.), Université de Paris, ENETS Centre of Excellence, Beaujon Hospital (APHP), Clichy, France; Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University Hospital Paolo Giaccone, Palermo, Italy (R.C., G.P.); Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy (R.C.); Université de Paris, Centre of Research on Inflammation, INSERM U1149, Paris, France (L.d.M., M.D., J.C., V.V., M.R.); Gustave Roussy, Département d'Anesthésie, Chirurgie et Interventionnel (DACI), Villejuif, France (L.T.); and Lausanne University Hospital and University of Lausanne, Department of Radiology and Interventional Radiology, Lausanne, Switzerland (R.D.).ORCID 0000-0001-7464-3939
Inserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose To investigate whether liver enhancing tumor burden (LETB) assessed at contrast-enhanced CT indicates early response and helps predict survival outcomes in patients with multifocal neuroendocrine liver metastases (NELM) after intra-arterial treatment. Materials and Methods This retrospective study included patients with NELM who underwent intra-arterial treatment with transarterial embolization (TAE) or chemoembolization (TACE) between April 2006 and December 2018. Tumor response in treated NELM was evaluated by using the Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST (mRECIST). LETB was measured as attenuation 2 SDs greater than that of a region of interest in the nontumoral liver parenchyma. Overall survival (OS); time to unTA(C)Eable progression, defined as the time from the initial treatment until the time when intra-arterial treatments were considered technically unfeasible, either not recommended by the multidisciplinary tumor board or until death; and hepatic and whole-body progression-free survival (PFS) were evaluated using multivariable Cox proportional hazards analyses, the Kaplan-Meier method, and log-rank test. Results The study included 119 patients (mean age, 60 years ± 11 [SD]; 61 men) who underwent 161 treatments. A median LETB change of -25.8% best discriminated OS (83 months in responders vs 51 months in nonresponders;

Indexed as

Chemoembolization, TherapeuticLiver NeoplasmsHumansMaleMiddle AgedRetrospective StudiesTomography, X-Ray ComputedTreatment OutcomeTumor BurdenAbdomen/GIChemoembolizationCTEmbolizationLiver

Identifiers

PMID36607243
PMCPMC9896229
OpenAlexW4313640011

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.